IV and Intrathecal Ketamine in Cesarean Section

Phase 4

Completed

• Conditions: Cesarean Section; Analgesia
• Interventions: Drug: Intrathecal ketamine; Drug: Intravenous ketamine

• Registration Number: NCT05679375
• Lead Sponsor: Assiut University

Brief Summary

In the current study, the investigators will compare the effects of low-dose intravenous (i.v.) ketamine versus intrathecal Ketamine added to spinal anesthesia on the time to first request for analgesia and maternal pain scores and overall satisfaction in patients undergoing cesarean section.

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2022-12-12
• Study First Submitted QC: 2022-12-24
• Study First Posted: 2023-01-11
• Study Start: 2023-02-01
• Primary Completion: 2024-10-31
• Study Completion: 2024-10-31
• Status Verified: 2025-03
• Last Update Submitted: 2025-03-04
• Last Update Posted: 2025-03-06

Recruitment & Eligibility

• Status: COMPLETED
• Sex: Female
• Target Recruitment: 60

Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Intrathecal Ketamine	Intrathecal ketamine	Patients will receive intrathecal Ketamine 0.1mg/kg added to bupivacaine and morphine.
Intravenous ketamine	Intravenous ketamine	Patients will receive IV Ketamine 0.25mg/kg after spinal anesthesia with bupivacaine and morphine.

Primary Outcome Measures

Name	Time	Method
Time to the first analgesic request	First Postoperative day

Secondary Outcome Measures

Name	Time	Method
Postoperative pain scores NRS at rest and on movement; (2, 4, 6, 12, and 24 hours) postoperative	first postoperative day

Trial Locations

Locations (1)

Assiut university; 🇪🇬 Assiut, Egypt